Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Bioregenx (BRGX) Common Equity (2021 - 2025)

Bioregenx has reported Common Equity over the past 5 years, most recently at -$4.5 million for Q4 2025.

  • For Q4 2025, Common Equity fell 34.27% year-over-year to -$4.5 million; the TTM value through Dec 2025 reached -$4.5 million, down 34.27%, while the annual FY2025 figure was -$4.5 million, 34.27% down from the prior year.
  • Common Equity for Q4 2025 was -$4.5 million at Bioregenx, down from -$3.6 million in the prior quarter.
  • Over five years, Common Equity peaked at $15.1 million in Q1 2024 and troughed at -$4.5 million in Q4 2025.
  • A 5-year average of $652984.5 and a median of -$2.4 million in 2023 define the central range for Common Equity.
  • Biggest five-year swings in Common Equity: crashed 2901.09% in 2022 and later soared 724.59% in 2024.
  • Year by year, Common Equity stood at -$84234.0 in 2021, then crashed by 2901.09% to -$2.5 million in 2022, then grew by 18.06% to -$2.1 million in 2023, then crashed by 63.14% to -$3.4 million in 2024, then tumbled by 34.27% to -$4.5 million in 2025.
  • Business Quant data shows Common Equity for BRGX at -$4.5 million in Q4 2025, -$3.6 million in Q3 2025, and -$3.7 million in Q2 2025.